Earnings results for F-star Therapeutics (NASDAQ:FSTX)
F-star Therapeutics, Inc. is estimated to report earnings on 03/12/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.55. The reported EPS for the same quarter last year was $-1.8.
Analyst Opinion on F-star Therapeutics (NASDAQ:FSTX)
2 Wall Street analysts have issued ratings and price targets for F-star Therapeutics in the last 12 months. Their average twelve-month price target is $35.00, predicting that the stock has a possible upside of 363.58%. The high price target for FSTX is $35.00 and the low price target for FSTX is $35.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”
F-star Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $35.00, F-star Therapeutics has a forecasted upside of 363.6% from its current price of $7.55. F-star Therapeutics has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: F-star Therapeutics (NASDAQ:FSTX)
F-star Therapeutics does not currently pay a dividend. F-star Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: F-star Therapeutics (NASDAQ:FSTX)
In the past three months, Evolus insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,135.00 in company stock. Only 10.10% of the stock of Evolus is held by insiders. Only 21.66% of the stock of Evolus is held by institutions.
Earnings and Valuation of F-star Therapeutics (NASDAQ:FSTX
Earnings for Evolus are expected to grow in the coming year, from ($1.95) to ($0.88) per share. The P/E ratio of Evolus is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Evolus is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Evolus has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here